Form 4: Privia Health Director Trades Under 10b5-1 Plan

Privia Health Group, Inc. Director Matthew Shawn Morris executed trades under a Rule 10b5-1 plan, involving the acquisition and disposition of common stock and stock options.

Summary

• Matthew Shawn Morris, a Director at Privia Health Group, Inc. (PRVA), engaged in transactions involving the company's common stock and stock options.
• These transactions were conducted under a pre-established Rule 10b5-1 trading plan, designed to comply with affirmative defense conditions.
• On June 26, 2026, Morris acquired 88,110 shares of common stock at a price of $2 per share and disposed of 88,110 shares at a weighted average price of $25.33.
• On June 29, 2026, Morris acquired an additional 63,212 shares of common stock at $2 per share and disposed of 63,212 shares at a weighted average price of $25.33.
• Following these transactions, Morris beneficially owns 76,651 shares directly and has indirect beneficial ownership of 12,487 shares through Emerald Family, LLC, and 11,998 shares through a Trust.
• The filing also details the status of stock options, with 88,110 options exercised on June 26, 2026, and 63,212 options exercised on June 29, 2026, all of which are fully vested and exercisable.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the significant sale of shares by a director, even though it was conducted under a Rule 10b5-1 plan.

Positives

• Director Matthew Shawn Morris's adherence to a Rule 10b5-1 trading plan indicates a structured and pre-planned approach to managing personal holdings, which can be viewed positively for corporate governance.
• The acquisition of shares at a lower price ($2) under the plan, followed by dispositions at a higher weighted average price (around $25.33), suggests a potentially favorable execution of the plan for the reporting person.
• The continued indirect beneficial ownership through Emerald Family, LLC and a Trust indicates ongoing commitment or interest in the company.

Negatives

• The disposition of a significant number of shares (88,110 on June 26 and 63,212 on June 29) by a Director could be interpreted negatively by the market, potentially signaling a lack of confidence or a need for liquidity.
• The weighted average sale price, while higher than the acquisition price, is subject to a range of prices, and the exact realization for all shares is not precisely detailed in the initial report.

Risks

• The primary risk associated with such transactions is the market's perception of insider selling, which can negatively impact share price, regardless of the structured nature of the trades.
• While the Rule 10b5-1 plan is intended to provide an affirmative defense against insider trading allegations, the execution of sales by a director can still create negative sentiment.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The reporting person undertakes to provide to Privia Health Group, Inc., any security holder of Privia Health Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing insider transactions are common for publicly traded companies. The use of Rule 10b5-1 plans by executives and directors is a standard practice to facilitate the sale of securities while adhering to insider trading regulations. The volume of shares traded by Director Morris is notable and will be closely watched by the market.

Corporate Governance

Stakeholder Impact

• Shareholders: May interpret the director's sales as a negative signal, potentially impacting share price. However, the Rule 10b5-1 plan provides a defense against insider trading accusations.
• Management: The transactions are conducted by a director, reflecting personal financial decisions within a regulatory framework.
• Creditors: No direct impact from these insider transactions.

Next Steps

• The reporting person may continue to execute trades under the Rule 10b5-1 plan.
• The company may be required to provide further details on specific sale prices upon request from the SEC or security holders.

Key Dates

Recommendation

The filing reports routine insider transactions under a Rule 10b5-1 plan. While the sale of a significant number of shares by a director can be a short-term negative signal, the structured nature of the trades under a pre-approved plan mitigates concerns about non-public information. Without further financial performance data or strategic updates, a 'hold' recommendation is prudent, suggesting investors monitor future filings and company performance.

Keywords

Privia Health Group, PRVA, Form 4, Insider Trading, Rule 10b5-1, Stock Options, Beneficial Ownership, Director Transactions, Matthew Shawn Morris, SEC Filing